Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: revenue declined 5% YoY, but gross margin improved to 65%. Despite a net loss, operational efficiencies reduced expenses by 8%. Revenue growth of 10-15% is expected, with a focus on new products and market expansion. However, lack of discussion on risks and returns, along with unclear Q&A responses, suggests caution. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Key Financial Performance
Revenue $15.2 million, a decrease of 5% year-over-year, primarily due to lower testing volumes.
Gross Margin 65%, an improvement from 62% year-over-year, driven by cost optimization initiatives.
Net Loss $3.8 million, compared to $4.5 million in the prior year, reflecting improved operational efficiencies.
Operating Expenses $10.5 million, a reduction of 8% year-over-year, attributed to strategic cost management.
Cash and Cash Equivalents $25 million, down from $30 million year-over-year, due to investments in technology upgrades.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The company is focusing on expanding its product portfolio and enhancing its technological capabilities to drive future growth.
Revenue Expectations: The company expects a revenue growth of 10% to 15% in the next fiscal year, driven by new product launches and market expansion.
Margin Projections: Operating margins are projected to improve by 2% due to cost optimization strategies and increased operational efficiencies.
Capital Expenditures: Capital expenditures are expected to increase by 5% to support infrastructure development and technological advancements.
Market Trends: The company anticipates a recovery in the healthcare market, with increased demand for diagnostic solutions.
Business Segment Performance: The diagnostics segment is expected to see significant growth, while other segments remain stable.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aballi CEO
Aballi President
BTIG LLC
Black CFO
Brennan TD
Canaccord Genuity
Capital
Director Jeffrey
Division Bonello
Division Brennan
Division EDT
Division Massaro
Division Parisi
EDT Greetings
Greetings Instructions
Investor Relations
Kyle Mikson
LLC Research
Mikson Canaccord
Officer Chief
President Investor
Relations Aballi
Relations Vice
Research Division
Secretary Kyle
Today Aballi
Today statement
Vice President
host Vice
presentation website
recording press
release Aballi
result Today
result slide
slide presentation
today measure
website Today
XGN Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents a mixed picture: revenue declined 5% YoY, but gross margin improved to 65%. Despite a net loss, operational efficiencies reduced expenses by 8%. Revenue growth of 10-15% is expected, with a focus on new products and market expansion. However, lack of discussion on risks and returns, along with unclear Q&A responses, suggests caution. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call presents a mixed outlook. While there is strong volume growth and positive trends in market expansion, the delay in profitability targets and ASP challenges weigh negatively. The Q&A reveals management's cautious stance on profitability timelines and ASP, which adds uncertainty. However, the company's strategic investments and potential ASP improvements, alongside strong relationships with ACR, provide a balance. Without market cap data, a neutral prediction (-2% to 2%) is reasonable, reflecting both positive growth aspects and financial uncertainties.
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary suggests mixed signals: positive revenue growth and ASP expansion are countered by challenges in achieving ASP targets and addressing payment denials. The Q&A section reveals management's unclear responses on key metrics, raising concerns. However, the strategic plan for 2025 shows optimism with new biomarker launches and potential pharma partnerships. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call reveals strong financial performance with improved gross margins and sustainable volume growth. Management is confident in achieving the ASP increase, and the strategic expansion of territories and pipeline developments are promising. Despite some increase in operating expenses and net loss, the company is on track for positive adjusted EBITDA and free cash flow. The Q&A section supports the positive outlook, highlighting market potential and strategic initiatives. While management avoided specific guidance on volume, the overall sentiment remains positive with expectations of continued growth.
XGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
